Is A Medicare Delay The Biggest Risk For DexCom Stock?
DexCom (DXCM) owners have one dated question left for 2026: will Medicare agree to pay for glucose monitors for people with type 2 diabetes who are not on insulin? DexCom said on its call after Q3 results that it expects CMS to announce that coverage decision this year, with DexCom’s current plan assuming coverage takes effect in the middle of 2027. By the close on Friday, Nov 13, no DexCom release had reported a coverage decision; its latest release before the close, on Nov 10, was about an upcoming conference presentation.
Our short answer: no, a delay is not the biggest risk. A delay would cost a near-term lift, not the business underneath. The decision is upside to a business that is already growing, not the whole case for the stock. Analysts already expect 2027 revenue about 10.4% above the midpoint of DexCom’s 2026 guidance, and even a yes would only start paying from mid-2027. So we think a yes would help only part of 2027, while a slip past year-end would take away a near-term lift.
The stock has already made back most of the drop that started this thread. DexCom fell 6.0% on Friday, Nov 6, the move What Is Behind The Move In DexCom Stock? looked at, and a reader of that piece asked us for more. It closed at $83.33 on Friday, Nov 13, 4.9% above the Nov 6 close, while the S&P 500 ETF rose 2.6% over the same days. It still sits 10.0% below its 52-week high.

Why Medicare’s answer matters to DexCom
DexCom’s U.S. share gains already lean on type 2 patients. The company said it gained U.S. share in Q3, with its largest increase coming from type 2 customers, including those not on insulin. U.S. revenue rose 14% to $970 million.
DexCom ties its confidence in a positive decision to CONNECT, its randomized trial in type 2 diabetes. The study was published in The New England Journal of Medicine, as DexCom announced on Oct 14. On its third-quarter earnings call, the company also said it expected the ADA standards of care to be updated in the coming weeks and looked forward to seeing the CONNECT evidence included.
What we cannot do is size the prize. Our data has no reliable count of the Medicare patients or the revenue at stake, so we don’t guess one. What a decision changes, in our view, is timing: a yes this year lines up with coverage from mid-2027 under DexCom’s plan, and a later answer would push that back.
The business without a Medicare yes
| Measure | Figure |
|---|---|
| Q3 revenue growth, year over year | 11.2% |
| Q3 U.S. revenue growth | 14% |
| Q3 international revenue growth | 5% |
| 2026 revenue guidance | $5.20-5.25 billion, 12% to 13% growth |
| 2026 non-GAAP operating margin guidance | 24%, raised |
| Diluted shares, Q3 2026 vs Q3 2025 | down 5.9% |
DexCom raised its 2026 revenue guidance to $5.20 billion to $5.25 billion. It said that puts it in the upper range of its original January guidance because it is tracking to a record year of new patient starts. Profit is rising faster than sales: on the basis DexCom used on its earnings call, which differs from GAAP, Q3 operating income was 25.3% of revenue, a higher share than a year earlier. It has finished its $1 billion buyback goal for 2026 and announced another $1 billion authorization. As of Sep 30, it held $1,817.9 million of cash and short-term investments against $1,392.9 million of debt.
What the price already assumes
At $83.33, DexCom trades at 30.8 times the analyst average for 2026 adjusted earnings per share and 26.5 times the 2027 average. That average has earnings per share growing 16.3% from 2026 to 2027. The stock is up 39.5% over the past year. For more on the multiple, see Is DexCom Stock Cheaper Now That Its Multiple Has Fallen?
Here is the tension: analysts expect growth to slow in 2027, and a Medicare yes could help only part of that year. The 2027 revenue consensus already implies 10.4% growth from the midpoint of DexCom’s 2026 guidance, a little below the 12% to 13% DexCom guides for 2026. We cannot size what a favorable decision would add to 2027 revenue. The clearer risk is a delay: a slip into 2027 would remove a near-term reason to own the stock without changing the business underneath.
Risks that do not depend on CMS
- Slower growth abroad. International revenue grew 5% in Q3, against 14% in the United States.
- Access. On the call, an analyst asked about a CVS contract described as lost. DexCom said the pharmacy benefit manager involved is less than 4% of its U.S. revenue, and that most patients who lose pharmacy coverage can still get its product through a medical benefit.
The test to watch this quarter
For an owner, this is a watch list, not a trade. First, the decision itself, which DexCom expects this year. Second, whether the ADA update includes the CONNECT evidence. Third, whether DexCom’s next update still points to the upper range of its original January guidance. If a yes arrives by year-end, it could help only part of 2027, since coverage would start mid-year under DexCom’s plan. If the decision slips, the case rests on the base business, which on the Q3 numbers is growing on its own. The risk for a new buyer is paying for the yes before it arrives.
Our conclusion: treat the Medicare decision as upside to a growing business, not the reason to own DexCom. The idea underneath is simple: a catalyst everyone is waiting for is rarely a surprise in the price, so the business under it has to do most of the work.
What to ask next
How does DexCom’s valuation compare with Abbott and other rivals? See Are You Overpaying For Abbott Stock Versus Its Rivals?
Is a stock waiting on one decision the right fit for your portfolio?
If you have $1 million or more invested, see what this means for your portfolio in a free 15-minute call with a Trefis partner firm.
For questions about this article or underlying research, email help@trefis.com.